2020
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising target
1999
Chapter 12 Fetal Grafts in Parkinson's Disease Primate Models
Sladek J, Collier T, Elsworth J, Roth R, Taylor J, Redmond D. Chapter 12 Fetal Grafts in Parkinson's Disease Primate Models. 1999, 321-364. DOI: 10.1016/b978-012705070-6/50013-5.Peer-Reviewed Original ResearchDisease patientsFetal tissue graftsParkinson's disease patientsProgressive neurological disorderEntire striatumParkinsonian symptomsFetal graftsClinical benefitDopaminergic neuronsSubstantia nigraClinical trialsNeurosurgical interventionPrimate modelParkinson's diseaseTissue graftDonor tissueNeurological disordersSource of cellsNeurodegenerative disordersFunctional changesProgressive lossHuman embryonic tissuesOptimal ageGraftSingle donor